These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 17569312

  • 1. [Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure].
    Aoyama N.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():145-9. PubMed ID: 17569312
    [No Abstract] [Full Text] [Related]

  • 2. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 3. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Nov 16; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 4. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S, Kitakaze M.
    Nihon Rinsho; 2003 May 16; 61(5):821-6. PubMed ID: 12755009
    [Abstract] [Full Text] [Related]

  • 5. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
    Lim S.
    Acta Med Indones; 2008 Jan 16; 40(1):34-7. PubMed ID: 19054878
    [Abstract] [Full Text] [Related]

  • 6. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 16; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 7. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul 16; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 8. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A, Majkowska L.
    Przegl Lek; 2007 Jul 16; 64(2):81-5. PubMed ID: 17892038
    [Abstract] [Full Text] [Related]

  • 9. Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin-angiotensin system.
    Guo X, Saini HK, Wang J, Gupta SK, Goyal RK, Dhalla NS.
    Expert Rev Cardiovasc Ther; 2005 Jul 16; 3(4):717-32. PubMed ID: 16076281
    [Abstract] [Full Text] [Related]

  • 10. Cellular basis for therapeutic choices in heart failure.
    Opie LH.
    Circulation; 2004 Oct 26; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract] [Full Text] [Related]

  • 11. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar 26; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 12. [Is it always necessary to use triple combination in the treatment of patients with chronic cardiac failure? Choice of the third neurohormonal blocker].
    Belenkov IuN, Mareev VIu, Skvortsov AA.
    Ter Arkh; 2008 Mar 26; 80(9):5-12. PubMed ID: 19555028
    [No Abstract] [Full Text] [Related]

  • 13. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z, Rogers JG.
    Curr Opin Cardiol; 2009 May 26; 24(3):223-9. PubMed ID: 19318933
    [Abstract] [Full Text] [Related]

  • 14. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H, Gilbert RE.
    J Hypertens; 2007 Jan 26; 25(1):25-35. PubMed ID: 17143168
    [Abstract] [Full Text] [Related]

  • 15. [Pharmacologic treatment of heart failure: general principle].
    Sasayama S.
    Nihon Rinsho; 2007 May 28; 65 Suppl 5():7-13. PubMed ID: 17571359
    [No Abstract] [Full Text] [Related]

  • 16. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 28; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 17. [Renin-angiotensin system modulation: instructions for use].
    Bellis A, Rozza F, Crispo S, Trimarco B.
    G Ital Cardiol (Rome); 2008 Feb 28; 9(2):79-89. PubMed ID: 18383770
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 28; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 28; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms for the clinical benefits of angiotensin II receptor blockers.
    Schmieder RE.
    Am J Hypertens; 2005 May 28; 18(5 Pt 1):720-30. PubMed ID: 15882557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.